Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/4682
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Whelan, KT | - |
dc.contributor.author | Pathan, AA | - |
dc.contributor.author | Sander, CR | - |
dc.contributor.author | Fletcher, HA | - |
dc.contributor.author | Poulton, I | - |
dc.contributor.author | Alder, NC | - |
dc.contributor.author | Hill, AVS | - |
dc.contributor.author | McShane, H | - |
dc.date.accessioned | 2011-01-10T15:34:58Z | - |
dc.date.available | 2011-01-10T15:34:58Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | PLoS ONE 4(6): e5934, June 2009 | en_US |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/4682 | - |
dc.description.abstract | Objectives: To investigate the safety and immunogenicity of a booster BCG vaccination delivered intradermally in healthy, BCG vaccinated subjects and to compare with a previous clinical trial where BCG vaccinated subjects were boosted with a new TB vaccine, MVA85A. Design: Phase I open label observational trial, in the UK. Healthy, HIV-negative, BCG vaccinated adults were recruited and vaccinated with BCG. The primary outcome was safety; the secondary outcome was cellular immune responses to antigen 85, overlapping peptides of antigen 85A and tuberculin purified protein derivative (PPD) detected by ex vivo interferongamma (IFN-c) ELISpot assay and flow cytometry. Results and Conclusions: BCG revaccination (BCG-BCG) was well tolerated, and boosting of pre-existing PPD-specific T cell responses was observed. However, when these results were compared with data from a previous clinical trial, where BCG was boosted with MVA85A (BCG-MVA85A), MVA85A induced significantly higher levels (.2-fold) of antigen 85-specific CD4+ T cells (both antigen and peptide pool responses) than boosting with BCG, up to 52 weeks post-vaccination (p = 0.009). To identify antigen 85A-specific CD8+ T cells that were not detectable by ex vivo ELISpot and flow cytometry, dendritic cells (DC) were used to amplify CD8+ T cells from PBMC samples. We observed low, but detectable levels of antigen 85A-specific CD8+ T cells producing IFNc (1.5% of total CD8 population) in the BCG primed subjects after BCG boosting in 1 (20%) of 5 subjects. In contrast, in BCG-MVA85A vaccinated subjects, high levels of antigen 85A-specific CD8+ T cells (up to 14% total CD8 population) were observed after boosting with MVA85A, in 4 (50%) of 8 subjects evaluated. In conclusion, revaccination with BCG resulted in modest boosting of pre-existing immune responses to PPD and antigen 85, but vaccination with BCG-MVA85A induced a significantly higher response to antigen 85 and generated a higher frequency of antigen 85A-specific CD8+ T cells. | en_US |
dc.description.sponsorship | Oxford University was the sponsor for all the clinical trials reported. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Public Library of Science | en_US |
dc.title | Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: Comparison with boosting with a new TB vaccine, MVA85A | en_US |
dc.type | Research Paper | en_US |
dc.identifier.doi | http://dx.doi.org/10.1371/journal.pone.0005934 | - |
Appears in Collections: | Biological Sciences Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 321.24 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.